chemo-displacement
ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions
ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management